questionText: To ask the Secretary of State for Health and Social Care, if he will make an estimate of the potential impact of prescribing abiraterone in England using the eligibility criteria used in (a) Scotland and (b) Wales on the number of premature deaths from high-risk, non-metastatic prostate cancer.
answerText: NHS England estimates that the number of eligible patients in England is between 7,500 and 9,500 per year. This is based on the same eligibility criteria as are used in Scotland and Wales. NHS England has not completed any specific work to estimate the po...
heading: Abiraterone